JPWO2019113181A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019113181A5 JPWO2019113181A5 JP2020531448A JP2020531448A JPWO2019113181A5 JP WO2019113181 A5 JPWO2019113181 A5 JP WO2019113181A5 JP 2020531448 A JP2020531448 A JP 2020531448A JP 2020531448 A JP2020531448 A JP 2020531448A JP WO2019113181 A5 JPWO2019113181 A5 JP WO2019113181A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- arginine
- peptide according
- animal
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims description 77
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
- 239000004475 Arginine Substances 0.000 claims description 44
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 44
- 235000009697 arginine Nutrition 0.000 claims description 44
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 36
- 241001465754 Metazoa Species 0.000 claims description 34
- 235000001014 amino acid Nutrition 0.000 claims description 28
- 229940024606 amino acid Drugs 0.000 claims description 28
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 24
- 239000004471 Glycine Substances 0.000 claims description 18
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 16
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 16
- 239000004472 Lysine Substances 0.000 claims description 16
- 235000018977 lysine Nutrition 0.000 claims description 16
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 16
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 12
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 12
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 12
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 12
- 235000004279 alanine Nutrition 0.000 claims description 12
- 235000009582 asparagine Nutrition 0.000 claims description 12
- 229960001230 asparagine Drugs 0.000 claims description 12
- 239000004474 valine Chemical group 0.000 claims description 12
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical group OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 8
- 235000003704 aspartic acid Nutrition 0.000 claims description 8
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- 241000009328 Perro Species 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- 206010040872 skin infection Diseases 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241000283707 Capra Species 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 4
- 241000282898 Sus scrofa Species 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 208000004396 mastitis Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 210000005075 mammary gland Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 238000011200 topical administration Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762595725P | 2017-12-07 | 2017-12-07 | |
| US62/595,725 | 2017-12-07 | ||
| PCT/US2018/064029 WO2019113181A1 (en) | 2017-12-07 | 2018-12-05 | Antimicrobial peptides and methods of using same |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021505624A JP2021505624A (ja) | 2021-02-18 |
| JPWO2019113181A5 true JPWO2019113181A5 (https=) | 2022-01-31 |
| JP2021505624A5 JP2021505624A5 (https=) | 2022-01-31 |
| JP7381465B2 JP7381465B2 (ja) | 2023-11-15 |
Family
ID=65003464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531448A Active JP7381465B2 (ja) | 2017-12-07 | 2018-12-05 | 抗菌ペプチドおよびそれを使用する方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11352396B2 (https=) |
| EP (2) | EP4656726A3 (https=) |
| JP (1) | JP7381465B2 (https=) |
| KR (3) | KR102555177B1 (https=) |
| CN (1) | CN111479824A (https=) |
| AR (1) | AR113618A1 (https=) |
| AU (3) | AU2018378035B2 (https=) |
| BR (1) | BR112020009973A2 (https=) |
| CA (1) | CA3082491A1 (https=) |
| CL (1) | CL2020001464A1 (https=) |
| CO (1) | CO2020006907A2 (https=) |
| DK (1) | DK3720875T3 (https=) |
| ES (1) | ES3041688T3 (https=) |
| FI (1) | FI3720875T3 (https=) |
| HU (1) | HUE072916T2 (https=) |
| IL (2) | IL275074B2 (https=) |
| LT (1) | LT3720875T (https=) |
| MX (1) | MX2020005920A (https=) |
| NZ (1) | NZ764838A (https=) |
| PH (1) | PH12020550942A1 (https=) |
| PL (1) | PL3720875T3 (https=) |
| PT (1) | PT3720875T (https=) |
| SG (1) | SG11202004661QA (https=) |
| SI (1) | SI3720875T1 (https=) |
| TW (2) | TWI786887B (https=) |
| WO (1) | WO2019113181A1 (https=) |
| ZA (1) | ZA202003387B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220307048A1 (en) * | 2021-03-23 | 2022-09-29 | Genvor Inc. | Antimicrobial peptides |
| CN113185576B (zh) * | 2021-04-09 | 2023-05-30 | 倪京满 | 一类具有RRRF转角的β-发卡型低毒广谱抗菌肽及其应用 |
| US20250042946A1 (en) | 2021-12-08 | 2025-02-06 | Oakgrove Bio Llc | Biological Production of Histidine-Rich Peptides |
| EP4198045A1 (en) * | 2021-12-16 | 2023-06-21 | Université de Lille | Antimicrobial peptides, variants and chemical analogues thereof and their uses |
| WO2024003890A1 (en) * | 2022-06-29 | 2024-01-04 | Omnix Medical Ltd. | Novel peptide for treating an infectious disease or condition |
| CN120309697B (zh) * | 2025-06-13 | 2025-09-02 | 四川大学 | 一种用于抗革兰氏阴性菌的多肽药物及应用 |
| CN121378418B (zh) * | 2025-12-26 | 2026-04-03 | 四川大学 | 一组针对革兰氏阴性菌的抗菌多肽 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1323166C (zh) * | 2003-09-18 | 2007-06-27 | 中国农业科学院饲料研究所 | 一种鲎素的基因及表达其的方法 |
| CN101307316B (zh) * | 2008-07-22 | 2011-03-16 | 北京中农颖泰生物技术有限公司 | 抗菌肽cad在枯草杆菌中的分泌表达及重组枯草杆菌表达系统 |
| CN101698682B (zh) * | 2009-10-26 | 2012-05-23 | 陕西省微生物研究所 | 一种基于抗菌肽的双功能融合蛋白及其制备方法和用途 |
| CN101817883B (zh) * | 2010-03-12 | 2012-06-13 | 广东药学院 | 一种家蝇天蚕素-人溶菌酶融合蛋白及其制备方法和应用 |
| CN101851620B (zh) * | 2010-04-21 | 2012-05-23 | 吉林农业大学 | 利用食药用菌生产FGFs的方法 |
| CA2890357C (en) * | 2011-07-13 | 2024-01-09 | Solarvest BioEnergy Inc. | Methods and uses of a modified cecropin for treating endoparasitic and bacterial infections |
| CN104177502B (zh) * | 2014-08-21 | 2018-04-24 | 天津兰瑞生物技术有限公司 | 一种鲎素肽-抗体融合蛋白及制备方法 |
| CN104988170B (zh) * | 2015-08-01 | 2018-01-16 | 吉林农业大学 | 一种融合抗菌肽及其制备方法和应用 |
-
2018
- 2018-11-28 TW TW110138439A patent/TWI786887B/zh active
- 2018-11-28 TW TW107142356A patent/TWI746908B/zh active
- 2018-12-05 EP EP25189644.5A patent/EP4656726A3/en active Pending
- 2018-12-05 SI SI201831260T patent/SI3720875T1/sl unknown
- 2018-12-05 KR KR1020207015602A patent/KR102555177B1/ko active Active
- 2018-12-05 PT PT188305627T patent/PT3720875T/pt unknown
- 2018-12-05 BR BR112020009973-2A patent/BR112020009973A2/pt unknown
- 2018-12-05 CN CN201880078731.4A patent/CN111479824A/zh active Pending
- 2018-12-05 WO PCT/US2018/064029 patent/WO2019113181A1/en not_active Ceased
- 2018-12-05 KR KR1020237023202A patent/KR102713813B1/ko active Active
- 2018-12-05 KR KR1020247032634A patent/KR20240151857A/ko active Pending
- 2018-12-05 US US16/769,025 patent/US11352396B2/en active Active
- 2018-12-05 IL IL275074A patent/IL275074B2/en unknown
- 2018-12-05 CA CA3082491A patent/CA3082491A1/en active Pending
- 2018-12-05 PL PL18830562.7T patent/PL3720875T3/pl unknown
- 2018-12-05 MX MX2020005920A patent/MX2020005920A/es unknown
- 2018-12-05 FI FIEP18830562.7T patent/FI3720875T3/fi active
- 2018-12-05 LT LTEPPCT/US2018/064029T patent/LT3720875T/lt unknown
- 2018-12-05 EP EP18830562.7A patent/EP3720875B1/en active Active
- 2018-12-05 HU HUE18830562A patent/HUE072916T2/hu unknown
- 2018-12-05 JP JP2020531448A patent/JP7381465B2/ja active Active
- 2018-12-05 IL IL312730A patent/IL312730A/en unknown
- 2018-12-05 ES ES18830562T patent/ES3041688T3/es active Active
- 2018-12-05 AU AU2018378035A patent/AU2018378035B2/en active Active
- 2018-12-05 SG SG11202004661QA patent/SG11202004661QA/en unknown
- 2018-12-05 NZ NZ764838A patent/NZ764838A/en unknown
- 2018-12-05 DK DK18830562.7T patent/DK3720875T3/da active
- 2018-12-06 AR ARP180103579A patent/AR113618A1/es unknown
-
2020
- 2020-06-02 CL CL2020001464A patent/CL2020001464A1/es unknown
- 2020-06-03 PH PH12020550942A patent/PH12020550942A1/en unknown
- 2020-06-04 CO CONC2020/0006907A patent/CO2020006907A2/es unknown
- 2020-06-05 ZA ZA2020/03387A patent/ZA202003387B/en unknown
-
2022
- 2022-05-06 US US17/738,572 patent/US12054518B2/en active Active
-
2023
- 2023-09-11 AU AU2023229465A patent/AU2023229465B2/en active Active
-
2024
- 2024-06-18 US US18/746,401 patent/US20250074947A1/en active Pending
- 2024-09-12 AU AU2024219645A patent/AU2024219645A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505624A5 (https=) | ||
| Vigneaud et al. | The synthesis of an octapeptide amide with the hormonal activity of oxytocin | |
| IL275074B2 (en) | Antimicrobial peptides and methods of using same | |
| RU2014103185A (ru) | Биологически активное соединение на основе лютеинизирующего гормона (lh) с пролонгированным действием | |
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| CN110945010A (zh) | 肽组合物和相关方法 | |
| JPWO2019113181A5 (https=) | ||
| JPH06228199A (ja) | 血液脳関門通過可能なペプチド結合体 | |
| JPH04504256A (ja) | ペプチド、免疫原性のある組成物、それを含むワクチンまたは製剤、哺乳動物にｌｈｒｈに対する免疫性を付与する方法および豚の肉質を向上させる方法 | |
| US10597426B2 (en) | Polypeptide compound and preparation method and use thereof | |
| CA2418793C (en) | Pharmaceutical composition comprising an analgesic peptide | |
| IL312731A (en) | Relaxin-2 fusion protein analogs and methods of using same | |
| US20180244724A1 (en) | Polypeptide compound and preparation method and use thereof | |
| JP2019038772A5 (https=) | ||
| RU2503684C2 (ru) | Иммуномодулирующие олигопептиды | |
| JP2021506815A5 (https=) | ||
| AU630591B2 (en) | Growth hormone related peptide | |
| EP3392263A1 (en) | Polypeptide compound, preparation method therefor and use thereof | |
| JP2018070571A (ja) | 免疫誘導剤 | |
| Mayer et al. | Fine tuning host responses in the face of infection: emerging roles and clinical applications of host defence peptides. | |
| US20170112940A1 (en) | Modified Collagen Hybridizing Peptides And Uses Thereof | |
| US11667674B2 (en) | Antibacterial cyclic lipopeptides | |
| JPH07309771A (ja) | 非経口用抗腫瘍剤 | |
| JPWO2021081601A5 (https=) | ||
| JPH0249734A (ja) | 新規組成物 |